FFilingSight

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Sep 5, 2026 · FilingSight Research

Market Brief — September 5, 2026

Risk-on · Supportive. 25 Buy / 120 Hold / 37 Sell across 182 names. Top conviction: INTU.

MacroDaily BriefRates

Market Brief — September 5, 2026

Auto-generated by FilingSight from live FRED macro data and the latest SEC-derived company reports.

Macro regime

Risk-on · Supportive.

Gauge Status Detail
Growth & Recession Gauge Healthy Healthy.
Inflation Regime Moderating Moderating. Headline CPI +3.3% YoY, core +2.5% YoY; 5Y breakeven 2.37%.
Financial Conditions Neutral Neutral. VIX 14.32, BAA-10Y credit spread 1.57pp.
Policy Stance Near neutral Near neutral. Fed funds 3.63%, real rate 1.16%.

Rates & inflation

Fed funds 3.63%, headline CPI YoY 3.3%, VIX 14.3, yield curve upward-sloping.

Coverage breadth

Across 182 tracked names: 25 bullish, 120 neutral, 37 bearish outlook.

Highest-conviction bullish names:

  • INTU (Intuit Inc.) — Buy, composite score 35, confidence 83%.
  • CF (CF Industries) — Buy, composite score 34, confidence 82%.
  • CME (CME Group Inc.) — Buy, composite score 32, confidence 81%.
  • MELI (MercadoLibre Inc.) — Buy, composite score 29, confidence 83%.

Most bearish names:

  • ON (ON Semiconductor Corp.) — Sell, score -44.
  • TSLA (Tesla Inc.) — Sell, score -40.
  • SBUX (Starbucks Corp.) — Sell, score -32.

What to watch

With the Fed on hold at 3.63% and inflation running at 3.3%, the supportive macro backdrop keeps risk appetite intact, but the sharp divergence between a narrow set of high-conviction buys and a broad hold camp signals selective positioning rather than broad-based accumulation. Watch for continued strength in INTU and MELI as earnings compounders, while CF and CME offer defensive cyclical and rate-sensitive hedges if the curve steepens further. A VIX near 14 leaves little cushion for surprises, so any CPI upside or hawkish Fed speak could quickly test the 25-name buy list's leadership.


FilingSight is informational and educational only, generated from public data. Not investment advice.